Oxidative Stress and Periodontal Disease in Down Syndrome

  • Tomoko KomatsuEmail author
  • Masaichi-Chang-Il LeeEmail author
Part of the Oxidative Stress in Applied Basic Research and Clinical Practice book series (OXISTRESS)


Down syndrome (DS) is caused by a unique metabolic imbalance induced by overexpression of genes on chromosome 21. The enzyme superoxide dismutase (SOD) is responsible for the regulation of reactive oxygen species (ROS) homeostasis. Increased levels or activity of SOD may contribute to neuronal death and disease progression in DS and precede the signature manifestations of the disease by decades. Individuals with DS have a higher prevalence and severity of periodontal disease, which cannot be explained by poor oral hygiene alone and is related to changes in the immune response. Using electron spin resonance (ESR) and spin trapping, we have obtained clear and direct evidence that ROS are generated in the media of cultured gingival cells from DS patients.

A number of findings in the past decade have prompted interest in the diagnostic use of saliva biomarkers. The salivary levels of oxidative stress biomarkers such as 8-hydroxy-2′-deoxyguanosine (8-OHdG) have been shown to be significantly higher in DS patients than in control subjects, suggesting that high oxidative stress may lead to some of the clinical features of DS, especially rapidly progressive periodontal disease associated with premature aging. In the future, analysis of biomarkers such as 8-OHdG in saliva samples could be useful for the assessment and management of periodontal disease with oxidative stress in DS patients.


Electron Spin Resonance Down Syndrome Periodontal Disease Poor Oral Hygiene Severe Periodontal Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This research was supported by a Grant-in-Aid for Scientific Research (no. 18592149 to M.L., no. 19592371 to T.K. and M.L., no. 23593049 to T.K., no. 23660047 to M.L.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.


  1. 1.
    Perluigi M, Butterfield DA (2012) Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia. Curr Gerontol Geriatr Res 2012:724904PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Schuchmann S, Heinemann U (2000) Increased mitochondrial superoxide generation in neurons from trisomy 16 mice: a model of Down’s syndrome. Free Radic Biol Med 28:235–250PubMedCrossRefGoogle Scholar
  3. 3.
    Busciglio J, Yankner BA (1995) Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature 378:776–779PubMedCrossRefGoogle Scholar
  4. 4.
    Komatsu T, Lee MC, Miyagi A et al (2006) Reactive oxygen species generation in gingival fibroblasts of Down syndrome patients detected by electron spin resonance spectroscopy. Redox Rep 11:71–77PubMedCrossRefGoogle Scholar
  5. 5.
    Hayakawa M, Hattori K, Sugiyama S et al (1992) Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts. Biochem Biophys Res Commun 189:979–985PubMedCrossRefGoogle Scholar
  6. 6.
    Campos C, Guzman R, Lopez-Fernandez E et al (2011) Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome. Biochim Biophys Acta 1812:760–768PubMedCrossRefGoogle Scholar
  7. 7.
    Sawamoto Y, Sugano N, Tanaka H et al (2005) Detection of periodontopathic bacteria and an oxidative stress marker in saliva from periodontal disease patients. Oral Microbiol Immunol 20:216–220PubMedCrossRefGoogle Scholar
  8. 8.
    Yasuda M, Ide H, Furuya K et al (2008) Salivary 8-OHdG: a useful biomarker for predicting severe ED and hypogonadism. J Sex Med 5:1482–1491PubMedCrossRefGoogle Scholar
  9. 9.
    Komatsu T, Duckyoung Y, Ito A et al (2013) Increased oxidative stress biomarkers in the saliva of Down syndrome patients. Arch Oral Biol 58:1246–1250PubMedCrossRefGoogle Scholar
  10. 10.
    Megarbane A, Ravel A, Mircher C et al (2009) The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet Med 11:611–616PubMedCrossRefGoogle Scholar
  11. 11.
    Frydman A, Nowzari H (2012) Down syndrome-associated periodontal disease: a critical review of the literature. Compend Contin Educ Dent 33:356–361PubMedGoogle Scholar
  12. 12.
    Hassold TJ, Jacobs PA (1984) Trisomy in man. Annu Rev Genet 18:69–97PubMedCrossRefGoogle Scholar
  13. 13.
    Cichon P, Crawford L, Grimm WD (1998) Early-onset periodontal disease associated with Down’s syndrome—clinical interventional study. Ann Periodontol 3:370–380PubMedCrossRefGoogle Scholar
  14. 14.
    Cohen MM, Winer RA, Schwartz S et al (1961) Oral aspects of mongolism. I: periodontal disease in mongolism. Oral Surg Oral Med Oral Pathol 14:92–107PubMedCrossRefGoogle Scholar
  15. 15.
    Roizen NJ, Patterson D (2003) Down’s syndrome. Lancet 361:1281–1289PubMedCrossRefGoogle Scholar
  16. 16.
    Sustrova M, Sarikova V (1997) Down’s syndrome—effect of increased gene expression in chromosome 21 on the function of the immune and nervous system. Bratisl Lek Listy 98:221–228PubMedGoogle Scholar
  17. 17.
    Pueschel SM (1990) Clinical aspects of Down syndrome from infancy to adulthood. Am J Med Genet Suppl 7:52–56PubMedGoogle Scholar
  18. 18.
    Smith DS (2001) Health care management of adults with Down syndrome. Am Fam Phys 64:1031–1038Google Scholar
  19. 19.
    Thiel R, Fowkes SW (2005) Can cognitive deterioration associated with Down syndrome be reduced? Med Hypotheses 64:524–532PubMedCrossRefGoogle Scholar
  20. 20.
    Zigman WB, Lott IT (2007) Alzheimer’s disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev 13:237–246PubMedCrossRefGoogle Scholar
  21. 21.
    Malt EA, Dahl RC, Haugsand TM et al (2013) Health and disease in adults with Down syndrome. Tidsskr Nor Laegeforen 133:290–294PubMedCrossRefGoogle Scholar
  22. 22.
    Teksen F, Sayli BS, Aydin A et al (1998) Antioxidative metabolism in Down syndrome. Biol Trace Elem Res 63:123–127PubMedCrossRefGoogle Scholar
  23. 23.
    Pallardo FV, Degan P, d’Ischia M et al (2006) Multiple evidence for an early age pro-oxidant state in Down syndrome patients. Biogerontology 7:211–220PubMedCrossRefGoogle Scholar
  24. 24.
    Cheon MS, Shim KS, Kim SH et al (2003) Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part IV). Amino Acids 25:41–47PubMedCrossRefGoogle Scholar
  25. 25.
    Midorikawa K, Kawanishi S (2001) Superoxide dismutases enhance H2O2-induced DNA damage and alter its site specificity. FEBS Lett 495:187–190PubMedCrossRefGoogle Scholar
  26. 26.
    de Teunissen CE, Vente J, Steinbusch HW et al (2002) Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiol Aging 23:485–508PubMedCrossRefGoogle Scholar
  27. 27.
    Brooksbank BW, Balazs R (1984) Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down’s syndrome fetal brain. Brain Res 318:37–44PubMedCrossRefGoogle Scholar
  28. 28.
    Gulesserian T, Seidl R, Hardmeier R et al (2001) Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med 49:41–46PubMedCrossRefGoogle Scholar
  29. 29.
    Gulesserian T, Engidawork E, Fountoulakis M et al (2001) Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J Neural Transm Suppl 61:71–84Google Scholar
  30. 30.
    de Haan JB, Cristiano F, Iannello RC et al (1995) Cu/Zn-superoxide dismutase and glutathione peroxidase during aging. Biochem Mol Biol Int 35:1281–1297PubMedGoogle Scholar
  31. 31.
    Muchova J, Sustrova M, Garaiova I et al (2001) Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med 31:499–508PubMedCrossRefGoogle Scholar
  32. 32.
    Pastore A, Tozzi G, Gaeta LM et al (2003) Glutathione metabolism and antioxidant enzymes in children with Down syndrome. J Pediatr 142:583–585PubMedCrossRefGoogle Scholar
  33. 33.
    Sikora E, Radziszewska E, Kmiec T et al (1993) The impaired transcription factor AP-1 DNA binding activity in lymphocytes derived from subjects with some symptoms of premature aging. Acta Biochim Pol 40:269–272PubMedGoogle Scholar
  34. 34.
    Moreira PI, Honda K, Zhu X et al (2006) Brain and brawn: parallels in oxidative strength. Neurology 66:S97–S101PubMedCrossRefGoogle Scholar
  35. 35.
    Zhu X, Raina AK, Perry G et al (2004) Alzheimer’s disease: the two-hit hypothesis. Lancet Neurol 3:219–226PubMedCrossRefGoogle Scholar
  36. 36.
    Orner G (1976) Periodontal disease among children with Down’s syndrome and their siblings. J Dent Res 55:778–782PubMedCrossRefGoogle Scholar
  37. 37.
    van Reuland-Bosma W, Dijk J (1986) Periodontal disease in Down’s syndrome: a review. J Clin Periodontol 13:64–73PubMedCrossRefGoogle Scholar
  38. 38.
    Seger R, Buchinger G, Stroder J (1977) On the influence of age on immunity in Down’s syndrome. Eur J Pediatr 124:77–87PubMedCrossRefGoogle Scholar
  39. 39.
    Mittwoch U (1958) The leucocyte count in children with mongolism. J Ment Sci 104:457–460PubMedGoogle Scholar
  40. 40.
    Barkin RM, Weston WL, Humbert JR et al (1980) Phagocytic function in Down syndrome—I: chemotaxis. J Ment Defic Res 24(Pt 4):243–249PubMedGoogle Scholar
  41. 41.
    Khan AJ, Evans HE, Glass L et al (1975) Defective neutrophil chemotaxis in patients with Down syndrome. J Pediatr 87:87–89PubMedCrossRefGoogle Scholar
  42. 42.
    Costello C, Webber A (1976) White cell function in Down’s syndrome. Clin Genet 9:603–605PubMedCrossRefGoogle Scholar
  43. 43.
    Gregory L, Williams R, Thompson E (1972) Leucocyte function in Down’s syndrome and acute leukaemia. Lancet 1:1359–1361PubMedCrossRefGoogle Scholar
  44. 44.
    Tan CV, Rosner F, Feldman F (1973) Nitroblue tetrazolium dye reduction in various hematologic disorders. N Y State J Med 73:952–956PubMedGoogle Scholar
  45. 45.
    Lee C, Miura K, Liu X et al (2000) Biphasic regulation of leukocyte superoxide generation by nitric oxide and peroxynitrite. J Biol Chem 275:38965–38972PubMedCrossRefGoogle Scholar
  46. 46.
    Babior BM (1984) The respiratory burst of phagocytes. J Clin Invest 73:599–601PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Chapple IL (1997) Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol 24:287–296PubMedCrossRefGoogle Scholar
  48. 48.
    Waddington RJ, Moseley R, Embery G (2000) Reactive oxygen species: a potential role in the pathogenesis of periodontal diseases. Oral Dis 6:138–151PubMedCrossRefGoogle Scholar
  49. 49.
    Lee MC, Kawai Y, Shoji H et al (2004) Evidence of reactive oxygen species generation in synovial fluid from patients with temporomandibular disease by electron spin resonance spectroscopy. Redox Rep 9:331–336PubMedCrossRefGoogle Scholar
  50. 50.
    Lee MC, Yoshino F, Shoji H et al (2005) Characterization by electron spin resonance spectroscopy of reactive oxygen species generated by titanium dioxide and hydrogen peroxide. J Dent Res 84:178–182PubMedCrossRefGoogle Scholar
  51. 51.
    Sherman L, Dafni N, Lieman-Hurwitz J et al (1983) Nucleotide sequence and expression of human chromosome 21-encoded superoxide dismutase mRNA. Proc Natl Acad Sci U S A 80:5465–5469PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Chen HI, Liou SH, Ho SF et al (2007) Oxidative DNA damage estimated by plasma 8-hydroxydeoxyguanosine (8-OHdG): influence of 4,4′-methylenebis (2-chloroaniline) exposure and smoking. J Occup Health 49:389–398PubMedCrossRefGoogle Scholar
  53. 53.
    Wu LL, Chiou CC, Chang PY et al (2004) Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 339:1–9PubMedCrossRefGoogle Scholar
  54. 54.
    Takane M, Sugano N, Ezawa T et al (2005) A marker of oxidative stress in saliva: association with periodontally-involved teeth of a hopeless prognosis. J Oral Sci 47:53–57PubMedCrossRefGoogle Scholar
  55. 55.
    Kaufman E, Lamster IB (2002) The diagnostic applications of saliva—a review. Crit Rev Oral Biol Med 13:197–212PubMedCrossRefGoogle Scholar
  56. 56.
    Hofman LF (2001) Human saliva as a diagnostic specimen. J Nutr 131:1621S–1625SPubMedGoogle Scholar
  57. 57.
    Branson BM (2004) FDA approves OraQuick for use in saliva: on March 25, the FDA approved the first rapid test for HIV in oral fluids. AIDS Clin Care 16:39PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Oral Science Dentistry for the Special PatientsKanagawa Dental UniversityYokosukaJapan
  2. 2.Yokosuka-Shonan Disaster Health Emergency Research Center & ESR LaboratoriesKanagawa Dental UniversityYokosukaJapan

Personalised recommendations